Experts initiate a discussion about concerns regarding the safety of using biologics in dermatology, particularly as monotherapy or in combination with topical corticosteroids for mild flaring or hotspot therapy. The conversation explores how well clinicians in various fields understand the safety of these treatments.

The experts emphasize the evolution of clinical trial protocols over time and the need for tailored treatment approaches based on patient, disease, and involvement area. The specificity of monoclonal antibodies in biologics is highlighted, focusing on the shift away from conventional DMARDs (disease-modifying antirheumatic drugs) and the importance of targeted mechanisms of action.

Specific biologics' mechanisms of action, such as tofacitinib and lebrikizumab, which inhibit the activation of interleukin pathways associated with skin diseases, are discussed. The favorable safety profiles of these medications are noted, with common adverse events being manageable, such as conjunctivitis.

The conversation addresses the shift from traditional therapies involving multiple topical agents and immunosuppressants, often requiring extensive monitoring and patient management. The newer biologics, with their specific targeting and favorable safety profiles, present a more streamlined and effective treatment option.

Positive clinical experiences over the decades are shared, witnessing the shift in conversations with patients. The discussion acknowledges the impressive impact of newer agents on patient lives, offering meaningful control of symptoms with a favorable risk-benefit ratio. The safety conversations around biologics are portrayed as reassuring to patients and their families, dispelling concerns and highlighting the drugs' positive impact on comfort and quality of life.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.